Vaxart, Inc.

VXRT ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2009
Operating Activities
Net Income $-18.7M
Depreciation & Amortization $502.0K
Depreciation —
Amortization —
Stock-Based Compensation $2.5M
Net Cash from Operating Activities $6.2M
Investing Activities
Capital Expenditures $4.0K
Business Acquisitions —
Net Cash from Investing Activities $-35.6M
Financing Activities
Dividends Paid —
Stock Repurchases $7.9M
Net Cash from Financing Activities $-17.5M
Net Change in Cash $-46.9M
Free Cash Flow $6.2M
← Newer Page 3 of 3 Older →